Proximal Location as a Predictor of Metachronous Colorectal Cancer After Excision of Adenomas.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: proximal vs
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[RESULTS] Compared with patients with only distal adenomas, patients with any proximal adenoma had a higher risk of metachronous CRC (1.70, 95% CI 1.17-2.45), proximal CRC (3.65, 95% CI 1.57-8.46), and AA (1.82, 95% CI 1.41-2.34). [DISCUSSION] Baseline adenoma proximal location is associated with future detection of CRC and AA.
[INTRODUCTION] To compare metachronous colorectal cancer (CRC) and advanced adenoma (AA) risk in patients with proximal vs.
- 95% CI 1.17-2.45
APA
Baile-Maxía S, Mangas-Sanjuán C, et al. (2025). Proximal Location as a Predictor of Metachronous Colorectal Cancer After Excision of Adenomas.. The American journal of gastroenterology, 120(11), 2719-2722. https://doi.org/10.14309/ajg.0000000000003505
MLA
Baile-Maxía S, et al.. "Proximal Location as a Predictor of Metachronous Colorectal Cancer After Excision of Adenomas.." The American journal of gastroenterology, vol. 120, no. 11, 2025, pp. 2719-2722.
PMID
40298225 ↗
Abstract 한글 요약
[INTRODUCTION] To compare metachronous colorectal cancer (CRC) and advanced adenoma (AA) risk in patients with proximal vs. distal adenomas.
[METHODS] We searched Pubmed, Embase, and Cochrane for cohort studies and clinical trials. Proximal adenomas were those located proximal to the descending colon. Pooled incidence rate ratios and 95% confidence intervals (CI) for CRC and AA were calculated using a random-effects model.
[RESULTS] Compared with patients with only distal adenomas, patients with any proximal adenoma had a higher risk of metachronous CRC (1.70, 95% CI 1.17-2.45), proximal CRC (3.65, 95% CI 1.57-8.46), and AA (1.82, 95% CI 1.41-2.34).
[DISCUSSION] Baseline adenoma proximal location is associated with future detection of CRC and AA.
[METHODS] We searched Pubmed, Embase, and Cochrane for cohort studies and clinical trials. Proximal adenomas were those located proximal to the descending colon. Pooled incidence rate ratios and 95% confidence intervals (CI) for CRC and AA were calculated using a random-effects model.
[RESULTS] Compared with patients with only distal adenomas, patients with any proximal adenoma had a higher risk of metachronous CRC (1.70, 95% CI 1.17-2.45), proximal CRC (3.65, 95% CI 1.57-8.46), and AA (1.82, 95% CI 1.41-2.34).
[DISCUSSION] Baseline adenoma proximal location is associated with future detection of CRC and AA.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
📖 전문 본문 읽기 PMC JATS · ~12 KB · 영문
CONFLICTS OF INTEREST
CONFLICTS OF INTEREST
Guarantor of the article: Rodrigo Jover, MD, PhD.
Specific author contributions: S.B.-M., C.M.-S., U.L., and R.J.: conceptualized and designed the study; C.S.A.: designed and run the literature search; S.B.-M., and C.M.-S.: acquired the data; S.B.-M., C.M.-S., P.Z., and R.J.: analyzed and interpreted the data and performed the statistical analysis; S.B.-M., C.M.-S. and R.J.: drafted the manuscript. All authors contributed to the critical revision of the manuscript for important intellectual content and approved the final version.
Financial support: This work was supported by the Instituto de Salud Carlos III (PI17/01756, PI20/01527, PI23/01974), Fundación de Investigación Biomédica de la Comunidad Valenciana–Instituto de Investigación Sanitaria y Biomédica de Alicante Foundation (UGP-24-095). Asociación para la Investigación en Gastroenterología de la Provincia de Alicante (AIGPA), a private association that promotes research in gastrointestinal diseases in Alicante, also supported the logistical aspects of the study, but declares no conflict of interest. The funding sources had no role in the study design, analysis, interpretation of data, writing or submission of the manuscript.
Potential competing interests: R.J. has received research grants from MSD, and has participated as an advisor to MSD, Norgine, Alpha-Sigma, and GISupply. U.L. has participated in the advisory board (UniversalDx, Lean Medical, Vivante, Kohler Ventures), and as consultant (Medtronic, Clinical Genomics, Guardant Health, Freenome, ChekCap). The rest of authors have nothing to disclose.
Data transparency statement: Data, analytic methods, and study materials will be made available to other researchers from the corresponding author (R.J.), upon reasonable request.
Guarantor of the article: Rodrigo Jover, MD, PhD.
Specific author contributions: S.B.-M., C.M.-S., U.L., and R.J.: conceptualized and designed the study; C.S.A.: designed and run the literature search; S.B.-M., and C.M.-S.: acquired the data; S.B.-M., C.M.-S., P.Z., and R.J.: analyzed and interpreted the data and performed the statistical analysis; S.B.-M., C.M.-S. and R.J.: drafted the manuscript. All authors contributed to the critical revision of the manuscript for important intellectual content and approved the final version.
Financial support: This work was supported by the Instituto de Salud Carlos III (PI17/01756, PI20/01527, PI23/01974), Fundación de Investigación Biomédica de la Comunidad Valenciana–Instituto de Investigación Sanitaria y Biomédica de Alicante Foundation (UGP-24-095). Asociación para la Investigación en Gastroenterología de la Provincia de Alicante (AIGPA), a private association that promotes research in gastrointestinal diseases in Alicante, also supported the logistical aspects of the study, but declares no conflict of interest. The funding sources had no role in the study design, analysis, interpretation of data, writing or submission of the manuscript.
Potential competing interests: R.J. has received research grants from MSD, and has participated as an advisor to MSD, Norgine, Alpha-Sigma, and GISupply. U.L. has participated in the advisory board (UniversalDx, Lean Medical, Vivante, Kohler Ventures), and as consultant (Medtronic, Clinical Genomics, Guardant Health, Freenome, ChekCap). The rest of authors have nothing to disclose.
Data transparency statement: Data, analytic methods, and study materials will be made available to other researchers from the corresponding author (R.J.), upon reasonable request.
Supplementary Material
Supplementary Material
출처: PubMed Central (JATS). 라이선스는 원 publisher 정책을 따릅니다 — 인용 시 원문을 표기해 주세요.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.